Kimmtrak Tebentafusp Sales Increase By 64% In 2023
In the battle against melanoma, Kimmtrak has emerged as a groundbreaking treatment that offers an innovative approach of treatment with significant commercial potential. Although Kimmtrak is currently only approved for the treatment of uveal melanoma, clinical trials are being conducted to…#tebentafusp #immunocore (Source: Reuters: Health)
Source: Reuters: Health - February 29, 2024 Category: Consumer Health News Source Type: news

Inaugural Award Poised to Advance Treatment Options for Uveal Melanoma Patients
CURE OM Team Award Earmarks a Significant Milestone for the Uveal Melanoma Population WASHINGTON , Feb. 16, 2024 /PRNewswire-PRWeb/ -- The Melanoma Research Foundation (MRF) recently announced the winners of the inaugural CURE OM Options Bring Hope Team Science Award: Bruce Ksander, PhD... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 17, 2024 Category: Pharmaceuticals Tags: AWD Source Type: news

Man told NHS will not fund £40k a time treatment
Craig Shore, who has ocular uveal melanoma, will have to pay up to £240,000 for chemosaturation. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - February 5, 2024 Category: Consumer Health News Source Type: news

Benefits of Tebentafusp in Uveal Melanoma Last 3 Years Benefits of Tebentafusp in Uveal Melanoma Last 3 Years
A new analysis suggests that the treatment ' s benefits for overall survival endures for at least 36 months.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 7, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Tebentafusp's OS Benefit in Uveal Melanoma Holds Up at 3 Years
(MedPage Today) -- MADRID -- The significant survival benefit with the bispecific T-cell receptor therapy tebentafusp (Kimmtrak) held up at 3 years for selected patients with previously untreated metastatic uveal melanoma, updated results of... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - October 22, 2023 Category: Dermatology Source Type: news

Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
(Source: Reuters: Health)
Source: Reuters: Health - October 22, 2023 Category: Consumer Health News Source Type: news

Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT ™ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma
HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma Approval includes treatment naïve and previously treated patients and is not limited by HLA genotype Delcath to hold Business Update Call on August 15, 2023 at 8:00 a.m. Eastern Time NEW YORK, Aug. 14,…#hepzatokit #fda #businessupdatecall #easterntime #delcathsystems #nccn #php #hepzatokitmarks #gerardmichel #nct02678572 (Source: Reuters: Health)
Source: Reuters: Health - August 16, 2023 Category: Consumer Health News Source Type: news

FDA OKs First Liver-Directed Treatment for Metastatic Uveal Melanoma
(MedPage Today) -- The FDA announced approval of the Hepzato Kit melphalan injection system as liver-directed therapy for uveal melanoma metastases. The approval stipulates use in adults with unresectable liver metastases that affects less than... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - August 15, 2023 Category: American Health Source Type: news

FDA approves melphalan as a liver-directed treatment for uveal melanoma
On August 14, 2023, the Food and Drug Administration approved HEPZATO KIT (melphalan for Injection/Hepatic Delivery System) containing melphalan (HEPZATO, Delcath Systems, Inc.) (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 15, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Hepzato Kit (melphalan) Hepatic Delivery System for the Treatment of Unresectable Hepatic-Dominant Metastatic Uveal Melanoma
NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that today the US Food and Drug Administration... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 14, 2023 Category: Drugs & Pharmacology Source Type: news

Determinants of Overall Survival in Metastatic Uveal Melanoma Identified
WEDNESDAY, July 12, 2023 -- Factors associated with improved survival in metastatic uveal melanoma include female sex and use of anti ‐cytotoxic T lymphocyte-associated antigen (CTLA)‐4 and anti‐programmed cell death protein 1 (PD-1) therapies,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 12, 2023 Category: Pharmaceuticals Source Type: news

Manglik, Arkin, Bastian receive Mark Foundation ASPIRE Award for moonshot cancer research
Funding from the Mark Foundation for Cancer Research will fuel high-risk, high-impact research on uveal melanoma. (Source: UCSF School of Pharmacy News)
Source: UCSF School of Pharmacy News - February 23, 2023 Category: Universities & Medical Training Source Type: news

Manglik, Arkin, Bastian receive ASPIRE Award for moonshot cancer research
Funding from the Mark Foundation for Cancer Research will fuel high-risk, high-impact research on uveal melanoma. (Source: UCSF School of Pharmacy News)
Source: UCSF School of Pharmacy News - February 23, 2023 Category: Universities & Medical Training Source Type: news

Treatment of Metastatic Uveal Melanoma in 2022 Treatment of Metastatic Uveal Melanoma in 2022
Recent developments in our understanding of metastatic uveal melanoma and treatment advancements have improved the prognosis of these patients. Find out what ' s new.Current Opinion in Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 2, 2022 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

Janssen to Highlight Latest Scientific Advances in Hematologic Diseases at ASH 2022 with Clinical and Real-World Data Across Innovative Pipeline and Distinguished Portfolio
RARITAN, N.J., November 3, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson are committed to redefining treatment outcomes in the hematology setting and today announced that abstracts from more than 50 company-sponsored studies, plus more than 20 investigator-initiated studies, will be presented at the American Society of Hematology (ASH) Annual Meeting in New Orleans from December 10-13, 2022. Janssen’s commitment to advancing an innovative portfolio of therapies for healthcare professionals and patients is evidenced through more than 70 presentations that span clinical studies and r...
Source: Johnson and Johnson - November 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news